MedTrace Logo

Developing and Implementing Familial Hypercholesterolemia Registry

NCT02865694 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-08-16

No results posted yet for this study

Summary

Familial hypercholesterolemia (FH) is a most prevalent genetic disorder define as high cholesterol level and premature death. The prevalence of FH reported in few countries however unknown in Iran. Thus determine the FH patient, finding diagnostic strategy and appropriate treatment are important. We intent to use cascade method to screening patients, also our expected outputs are to develop and implement a registry program for FH patients and their families and to study their genetic disorder. FH patients will be followed from management, treatment and prevention of Cardio vascular disease in order to increase premature death.

Conditions

  • Familial Hypercholesterolemia

Interventions

OTHER

Cascade

Sponsors & Collaborators

  • Isfahan University of Medical Sciences

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-09-30
Completion
2021-09-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02865694 on ClinicalTrials.gov